<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438408</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0285</org_study_id>
    <nct_id>NCT04438408</nct_id>
  </id_info>
  <brief_title>National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.</brief_title>
  <acronym>2ndsouffle</acronym>
  <official_title>National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SECOND SOUFFLE survey focuses on aspects of care and quality of life in a period when the&#xD;
      landscape of severe asthma is changing in the context of biotherapies. Moreover survey on&#xD;
      care pathway and quality of life of the asthmatic severe population according to their&#xD;
      phenotype have never been done. It is likely to bring results in a relatively fast time,&#xD;
      results that can lead to guide the criteria collected in RAMSES a national severe asthma&#xD;
      cohort and future research tracks of this cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Th2 phenotype corresponds to severe asthmatic patients eligible for new subcutaneous&#xD;
      targeted asthma therapies, which can bring about a real improvement in symptoms and quality&#xD;
      of life. No data are available on the proportion of this patient population since the advent&#xD;
      of biotherapies, as well as the impact on quality of life and pathway by phenotype.&#xD;
&#xD;
      The survey will be conducted using a collection of data on a dedicated questionnaire&#xD;
      including validated questionnaires on the quality of life and the control of the asthmatic&#xD;
      disease as well as the therapeutic observance.&#xD;
&#xD;
      The objectives of the survey are to estimate the phenotypic profile distribution of severe&#xD;
      asthmatic patients and the proportion currently treated by biotherapies as well as the impact&#xD;
      of the pathology on the clinical profile and quality of life of patients with severe asthma.&#xD;
&#xD;
      Investigative pulmonologists selected from university or general hospitals or from private&#xD;
      practice will propose to their eligible patients to participate in the study. Patients&#xD;
      informed and not opposed to participating will complete, at the end of the consultation, the&#xD;
      dedicated questionnaire pre-filled by the pulmonologist (for the medical data required for&#xD;
      phenotypic stratification). The questionnaires will be collected from the centers and the&#xD;
      data centralized to establish the database. Analyzes will be done in order to stratify the&#xD;
      populations according to their phenotype and to analyze the data globally and by subgroup.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stratification of severe asthmatics in 3 phenotypes</measure>
    <time_frame>12 months</time_frame>
    <description>The severe asthmatics patients will stratified in 3 phenotypes groups: Th2 phenotype with biotherapy, Th2 phenotype without biotherapy and non-Th2 phenotype</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Asthma Chronic</condition>
  <condition>Severe Asthma</condition>
  <arm_group>
    <arm_group_label>severe asthma patient</arm_group_label>
    <description>Adult patients (â‰¥ 18 years) with diagnosis of severe asthma for at least 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionaires</intervention_name>
    <description>patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.</description>
    <arm_group_label>severe asthma patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with confirmed diagnosis of severe asthma for at least 12 months&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of severe asthma for at least 12 months confirmed by a respiratory&#xD;
             physicians and meeting the ATS / ERS definition,&#xD;
&#xD;
          -  Social insured patient,&#xD;
&#xD;
          -  Patient given the non-opposition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient participating in a therapeutic clinical trial&#xD;
&#xD;
          -  Patient opposing participation in this study&#xD;
&#xD;
          -  Patient with reading and comprehension difficulties not allowing him to complete the&#xD;
             questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Alain, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain DIDIER, Pr</last_name>
    <phone>05.67.77.18.50</phone>
    <phone_ext>+33</phone_ext>
    <email>didier.a@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle OLIVIER, PhD</last_name>
    <phone>0561777051</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.i@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UHToulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Didier, Pr</last_name>
      <phone>05 67 77 18 30</phone>
      <phone_ext>+33</phone_ext>
      <email>didier.a@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle OLIVIER, PhD</last_name>
      <phone>0561777051</phone>
      <phone_ext>+33</phone_ext>
      <email>olivier.i@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alain DIDIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent GUILLEMINAULT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Asthma</keyword>
  <keyword>Th2 phenotype</keyword>
  <keyword>Care pathway</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

